#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Prediction and prevention of diabetes mellitus type 2


Authors: M. Kvapil
Authors‘ workplace: Interní klinika 2. LF UK a FN v Motole, Praha
Published in: Kardiol Rev Int Med 2011, 13(2): 87-91

Overview

Diabetes mellitus type 2 is a genetically determined disease. Currently, prediction of diabetes based on the identification of risk genes is not sufficiently contributive with respect to polygenic inheritance. The time when diabetes manifests or whether it manifests at all is related to regimen, the accumulation of body fat, physical activity and, as becomes evident, also to the manner of treatment of comorbidities (hypertension, hyperlipoproteinemia). In persons who are at risk with respect to diabetes manifestation and who significantly change their regimen, alter dietetic habits and incorporate physical activity in their everyday program (often also reducing their body weight), there is much less probability that diabetes will develop. By combining certain antidiabetic drugs and altering regimen, even better results can be achieved.

Keywords:
prevention – diabetes mellitus


Sources

1. Jensen MD. Adipose tissue and fatty acid metabolism in humans. J R Soc Med 2002; 95 (Suppl 42): 3–7.

2. Tuomilehto J, Lindström J, Eriksson JG et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350.

3. Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.

4. Diabetes Prevention Program Research Group. Knowler WC, Fowler SE, Hamman RF et al. 10-year follow-up of diabetes incidence and weight loss in the Dia­betes Prevention Program Outcomes Study. Lancet 2009; 374: 1677–1686.

5. Howlett HCS, Bailey CJ. A risk – benefit assessment of metformin in type 2 Diabetes Mellitus. Drug Saf 1999; 20: 489–503.

6. Zinman B, Harris SB, Neuman J et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010; 376: 103–111.

7. Chiasson JH, Josse RG, Gomis R et al. STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabettes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072–2077.

8. Kawamori R, Tajima N, Iwamoto Y et al. Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009; 373: 1607–1614.

9. Sjostrom L et al. XENDOS (Xenical in the prevention of Diabetes in Obese Subjects): a landmark study. Presentation in EASD 2002, Budapest.

10. Kahn SE, Haffner SM, Heise MA et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or gliburide monotherapy. N Engl J Med 2006; 355: 2427–2443.

11. NAVIGATOR Study Group. Holman RR, Haffner SM, McMurray JJ. Effect of nateglinide on the incidence of ­diabetes and cardiovascular events. N Engl J Med 2010; 362: 1463–1476.

12. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial investigators. Gerstein HC, Yusuf S, Bosch J. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096–1105.

13. DREAM Trial investigators. Bosch J, Yusuf S, Gerstein HC. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551–1562.

14. Astrup A, Rössner S, Van Gaal L et al. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 7; 374: 1606–1616.

15. Gruber A, Nasser K, Smith R et al. Diabetes prevention: is there more to it than lifestyle changes? Int J Clin Pract 2006; 60: 590–594.

16. Meneghini LF. Impact of bariatric surgery on type 2 diabetes. Cell Biochem Biophys 2007; 48: 97–102.

17. Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and metaanalysis. Am J Med 2009; 122: ­248–256.

18. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular mortality and morbidity in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353: 611–616.

19. Yusuf S, Sleight P, Pogue J et al. Effects of an angio­tensin-converting-enzyme inhibitor, ramipril, on cardovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.

20. Bosch J, Lonn E, Pogue J et al. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112: 1339–1346.

21. Lindholm LH, Ibsen H, Borch-Johnsen K et al. LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879–1886.

22. The Antihypertensive and Lipid – Lovering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 1981–1997.

23. Cooper-Dehoff R, Cohen JD, Bakris GL et al. INVEST Investigators. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 2006; 98: 890–894.

24. NAVIGATOR Study Group. McMurray JJ, Holman RR, Haffner SM. Effect of valsartan on the incidence of dia­betes and cardiovascular events. Engl J Med 2010; 362: 1477–1490.

25. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (metaanalysis of randomized trials). Am J Cardiol 2007; 99: 1006–1012.

26. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative metaanalysis of randomised statin trials. Lancet 2010; 375: 735–742.

27. Cholesterol Treatment Trialists' (CTT) Collaborators. Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering herapy in 18,686 people with dia­betes in 14 randomised trials of statins: a metaanalysis. Lancet 2008; 371: 117–125.

28. American Diabetes Asociation. Standards of Medical Care in Diabetes – 2011. Diabetes Care 2010: 34 (Suppl): S11–S61.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#